ArticleBMJ open respiratory research2026
Prognostic value of ventilatory efficiency in hypersensitivity pneumonitis.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tidal Volume in Idiopathic Pulmonary Fibrosis: Restriction Severity and Prognostic Information beyond Forced Vital Capacity.Respiration; international review of thoracic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentilatory efficiency (VE) from cardiopulmonary exercise testing (CPET) is a valuable prognostic metric for evaluating cardiopulmonary diseases. However, its relationship with clinical outcomes in hypersensitivity pneumonitis (HP) remains unclear. We aimed to determine whether VE correlates with disease severity and predicts mortality in HP. RESEARCH QUESTION: In patients with HP, does VE correlate with disease severity and predict mortality?
methodsThis retrospective cohort study (2009-2019) included patients with non-fibrotic (nfHP) and fibrotic HP (fHP) and idiopathic pulmonary fibrosis (IPF), which served as the comparison group. CPET variables, including VE/carbon dioxide (VE/VCO
results164 patients were analysed (mean age of 65.6±12.0 years, 54.3% male). 25 had nfHP, 66 fHP and 73 IPF. Overall, an increase in the VE/VCO
interpretationIn patients with HP, elevated VE/VCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.